Mortality of multiple sclerosis in Iceland population-based mortality of MS in incidence and prevalence cohorts.

Olöf Eliasdottir, Ólafur Kjartansson, Elias Olafsson
{"title":"Mortality of multiple sclerosis in Iceland population-based mortality of MS in incidence and prevalence cohorts.","authors":"Olöf Eliasdottir,&nbsp;Ólafur Kjartansson,&nbsp;Elias Olafsson","doi":"10.1177/20552173231169467","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mortality is an important feature of the natural history of multiple sclerosis (MS). We report the mortality of all individuals with MS in Iceland, identified in a nationwide population-based study.</p><p><strong>Patients and methods: </strong>The results are based on a prevalence cohort and an incidence cohort. The prevalence cohort consisted of all patients with MS (n = 526) living in Iceland on the 31 December 2007. The incidence cohort consisted of all residents of Iceland (n = 222) diagnosed with MS during 2002 to 2007. Mortality was determined by following both the incidence cohort (from diagnosis) and the prevalence cohort (from the prevalence day) until death or 31 December 2020. The mortality, associated with MS, was compared with that expected in the Icelandic population (<i>standardized mortality ratio</i> (SMR)).</p><p><strong>Results: </strong>(a) Prevalence cohort (n = 526). The mean follow up was 12.0 years (range 0.3-13.0). The SMR was 1.6 (95% confidence interval (CI) 1.3-2.0). (b) Incidence cohort (n = 222). The mean follow up was 15.4 years (range 3.7-18.5). The SMR was 1.2 (95% CI 0.6-2.2).</p><p><strong>Conclusion: </strong>During the follow-up period, there was a substantial increase in mortality among the patients with MS, compared with the general population. There was no increase in mortality among the incidence cohort, when followed for up to 18.5 years following diagnosis.</p>","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/96/10.1177_20552173231169467.PMC10134140.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20552173231169467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Mortality is an important feature of the natural history of multiple sclerosis (MS). We report the mortality of all individuals with MS in Iceland, identified in a nationwide population-based study.

Patients and methods: The results are based on a prevalence cohort and an incidence cohort. The prevalence cohort consisted of all patients with MS (n = 526) living in Iceland on the 31 December 2007. The incidence cohort consisted of all residents of Iceland (n = 222) diagnosed with MS during 2002 to 2007. Mortality was determined by following both the incidence cohort (from diagnosis) and the prevalence cohort (from the prevalence day) until death or 31 December 2020. The mortality, associated with MS, was compared with that expected in the Icelandic population (standardized mortality ratio (SMR)).

Results: (a) Prevalence cohort (n = 526). The mean follow up was 12.0 years (range 0.3-13.0). The SMR was 1.6 (95% confidence interval (CI) 1.3-2.0). (b) Incidence cohort (n = 222). The mean follow up was 15.4 years (range 3.7-18.5). The SMR was 1.2 (95% CI 0.6-2.2).

Conclusion: During the follow-up period, there was a substantial increase in mortality among the patients with MS, compared with the general population. There was no increase in mortality among the incidence cohort, when followed for up to 18.5 years following diagnosis.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
冰岛多发性硬化症的死亡率:发病率和患病率队列中基于人群的MS死亡率。
死亡率是多发性硬化症(MS)自然史的一个重要特征。我们报告了冰岛所有MS患者的死亡率,这是在一项全国性的基于人群的研究中确定的。患者和方法:研究结果基于患病率队列和发病率队列。患病率队列包括2007年12月31日居住在冰岛的所有MS患者(n = 526)。发病率队列包括2002年至2007年间诊断为多发性硬化症的所有冰岛居民(n = 222)。通过跟踪发病率队列(自诊断起)和患病率队列(自患病率日起)直至死亡或2020年12月31日,确定死亡率。将与多发性硬化症相关的死亡率与冰岛人口的预期死亡率(标准化死亡率(SMR))进行比较。结果:(a)患病率队列(n = 526)。平均随访时间为12.0年(0.3-13.0年)。SMR为1.6(95%置信区间(CI) 1.3 ~ 2.0)。(b)发病率队列(n = 222)。平均随访时间为15.4年(3.7-18.5年)。SMR为1.2 (95% CI 0.6-2.2)。结论:在随访期间,MS患者的死亡率与一般人群相比有明显增加。在确诊后18.5年的随访中,发病率队列的死亡率没有增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.70
自引率
0.00%
发文量
54
审稿时长
15 weeks
期刊最新文献
Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis. Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis-A systematic review and meta-analysis. Cesarian sections in women with multiple sclerosis: A Canadian prospective pregnancy study. Exploring the relationship between neurologists and older persons with multiple sclerosis through the lens of social support theory. Illness representation in patients with multiple sclerosis: A preliminary narrative medicine study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1